You are here: Industry Insights > ARDS

News List

Apellis Initiates Study of APL-9 in Patients with Severe COVID-19 americanpharmaceuticalreview
June 04, 2020
Apellis Pharmaceuticals announced the company has initiated a Phase 1/2 clinical study of APL-9, an investigational C3 inhibitor designed for acute interventions ...
Aerpio, Quantum Leap Select Razuprotafib as Potential Treatment for COVID-19 ARDS americanpharmaceuticalreview
June 02, 2020
Aerpio Pharmaceuticals and Quantum Leap Healthcare Collaborative™ announced an agreement has been reached to evaluate razuprotafib in a new randomized ...
Glucocorticoids are harmful in treating viral respiratory infections worldpharmanews
June 01, 2020
Glucocorticoids are widely used in treating acute respiratory distress syndrome (ARDS) despite there being no indisputable scientific evidence of their effectiveness.
Experimental stem cell therapy trial for COVID-19 initiated europeanpharmaceuticalreview
May 29, 2020
Researchers announce the first patient has been dosed in a trial testing remestemcel-L, a stem cell therapy, in severe COVID-19 patients on ventilators.
Roivant Releases Gimsilumab Trial Updates for ARDS Prevention, Treatment for COVID-19 Patients americanpharmaceuticalreview
May 20, 2020
Roivant Sciences announced several updates for its adaptive, randomized, double-blind, placebo-controlled, multi-center pivotal BREATHE trial ...
Enzychem Initiates EC-18 Study to Prevent ARDS due to Coronavirus Pneumonia americanpharmaceuticalreview
May 19, 2020
Enzychem Lifesciences announced the Ministry of Food and Drug Safety (MFDS, formerly the Korea Food and Drug Administration), has accepted its Investigational New Drug (IND) application to initiate a Phase 2 study for its lead therapeutic candidate.
Exvastat wins 3.6m euro grant for COVID-19 trial pharmatimes
May 15, 2020
Privately-held biopharma Exvastat (Ireland) Ltd has won a 3.6 million euro grant from the Innovative Medicines Initiative following its call for developers to repurpose imatinib for the treatment of Acute Respiratory Distress Syndrome (ARDS) induced by CO
SeaStar to Study Selective Cytopheretic Device in COVID-19 Patients with ARDS, Kidney Injury americanpharmaceuticalreview
May 04, 2020
SeaStar Medical has received approval of their Investigational Device Exemption (IDE) supplement from the U.S. Food and Drug Administration (FDA) to initiate a feasibility, compassionate use study.
ILC Therapeutics Discovers Novel Potential Covid-19 Treatments contractpharma
May 04, 2020
ILC Therapeutics has discovered two separate novel treatments for Covid-19 patients before they are put on ventilators. The UK-based firm is now urgently seeking funding of £4 million to accelerate safety studies and clinical trials.
Santhera, Cold Spring Harbor Lab to Investigate Lonodelestat in COVID-19-related ARDS americanpharmaceuticalreview
April 30, 2020
Santhera Pharmaceuticals has entered into a collaboration agreement with Cold Spring Harbor Laboratory (CSHL) to investigate the potential of lonodelestat (POL6014), a potent inhibitor of human neutrophil elastase (hNE).

Previous page 1 2 3 4 5 6 7 Next page